Enjoy complimentary customisation on priority with our Enterprise License!
The ent disorder treatment market share is expected to increase by USD 9.09 billion from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 13.23%.
This ent disorder treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers ent disorder treatment market segmentations by indication (rhinitis, sinusitis, otitis media, and tonsillitis) and geography (North America, Europe, APAC, South America, and MEA). The ent disorder treatment market report also offers information on several market vendors, including AbbVie Inc., ALK-Abello AS, Bayer AG, Covis Pharma BV, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., and Sanofi SA among others.
Download Report Sample to Unlock the ENT Disorder Treatment Market Size for the Forecast Period and Other Important Statistics
Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The rapid environmental deterioration resulting in several allergic conditions is notably driving the ent disorder treatment market growth, although factors such as limitations of existing therapies and availability of substitutes may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the ent disorder treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key ENT Disorder Treatment Market Driver
Rapid environmental deterioration resulting in several allergic conditions is one of the key factors driving the growth of the global ENT disorder treatment market. Environmental changes can worsen allergic conditions, including ENT disorders such as sinusitis, rhinitis, and tonsillitis. Owing to an increase in industrialization, there have been significant changes in many environmental factors. These changes can be largely attributed to an increase in the use of chemical substances, especially in the agricultural or manufacturing industries. Researchers and healthcare providers believe that several environmental pollutants, such as air pollutants and chemical substances, can worsen various allergies and ENT disorders. For instance, diesel exhaust particles (DEPs), which are an agglomeration of particles and a wide array of chemical substances, aggravate asthma, primarily due to the principle organic chemical components of DEPs. Many studies reveal that chronic sinus problems are common in areas with high air pollution levels. Such factors will increase the market focus during the forecast period.
Key ENT Disorder Treatment Market Trend
Growing awareness among people about ENT disorder treatment will fuel the global ENT disorder treatment market growth. The global ENT disorder treatment market is currently witnessing an increase in the efforts by both government and private organizations to improve drug development and the adoption of drugs among patients. The US FDA has laid guidelines for the development of therapeutics for ENT disorders such as acute bacterial sinusitis (ABS). According to the US FDA, ABS is defined as a medical condition that is characterized by the inflammation of the paranasal sinus glands, which is caused by the bacterial pathogen present within the sinus gland. The duration of the condition is less than a month. The US FDA guidelines intend to raise awareness about the drug development approach and clinical trial designs for ENT disorder drugs to support the therapeutic regimen for ABS. Moreover, to promote awareness about the symptoms and treatment of allergic diseases such as sinusitis, the Asthma, and Allergy Foundation of America (AAFA), a non-profit organization founded in 1953, is providing patient education. AAFA is a leading patient organization for people diagnosed with asthma and allergies. Such initiatives are anticipated to fuel the volume consumption of ENT drugs among people during the forecast period.
Key ENT Disorder Treatment Market Challenge
Limitations of existing therapies and the availability of substitutes are major challenges for the global ENT disorder treatment market growth. Most ENT disorders are allergic in nature, and many antibiotics are prescribed for the treatment of ENT disorders. These antibiotics have some limitations, particularly microbial resistance. Antibiotic resistance is increasing in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening the ability to treat ENT disorders. Antibiotics can be bought for human or animal use without a prescription, and the microbial resistance is worsened further. Furthermore, in countries without standard treatment guidelines, antibiotics are often overprescribed by health workers and veterinarians and overused by the public. Overprescribing antibiotics is a major concern nowadays. It is estimated that out of the total prescriptions, about 90% of the prescriptions are antibiotics, and respiratory tract infections and respiratory disorders are some of the major reasons for prescriptions. Moreover, the limitations of the therapeutics available, the high success rate of surgery in chronic rhinosinusitis patients, and the availability of home remedies are expected to encourage people to adopt alternative options for the treatment of ENT disorders, which is expected to hinder the growth of the market during the forecast period.
This ent disorder treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Technavio categorizes the ENT disorder treatment market as a part of the pharmaceutical market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the ent disorder treatment market during the forecast period.
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
This statistical study of the ent disorder treatment market encompasses successful business strategies deployed by the key vendors. The ent disorder treatment market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The ent disorder treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the ent disorder treatment market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the global pharmaceutical market includes the following core components:
The report has further elucidated on other innovative approaches being followed by service providers to ensure a sustainable market presence.
For more insights on the market share of various regions Request PDF Sample now!
40% of the market’s growth will originate from North America during the forecast period. The US is the key market for ent disorder treatment market in North America. Market growth in this region will be slower than the growth of the market in regions.
Rapid environmental deterioration resulting in several allergic conditions will facilitate the ent disorder treatment market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The ENT disorder treatment market in North America has been experiencing fluctuations in growth due to the COVID-19 pandemic. Physicians and patients have been avoiding non-urgent surgeries in order to limit the spread of COVID-19, which has led to a decline in uptake of ENT procedures. In addition, the majority of ENT conditions have alternative treatment options such as medical drugs that specially help in cases with early detection. However, in 2021, the initiation of large-scale vaccination drives lifted the lockdown and travel restrictions, which led to the resumption of supply chain activities. Such factors are expected to drive the market during the forecast period.
To gain further insights on the market contribution of various segments Request PDF Sample
The ent disorder treatment market share growth by the Rhinitis segment will be significant during the forecast period. Rhinitis is a condition that affects the nose, throat, and lungs of the person. It is caused by the inflammation of the mucosa in the lining of the nasal cavity. Noninflammatory conditions are often grouped with rhinitis. However, this is inappropriate as the mechanisms are distinctly different.
This report provides an accurate prediction of the contribution of all the segments to the growth of the ent disorder treatment market size and actionable market insights on post COVID-19 impact on each segment.
ENT Disorder Treatment Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 13.23% |
Market growth 2021-2025 |
$ 9.09 billion |
Market structure |
Fragmented |
YoY growth (%) |
48.08 |
Regional analysis |
North America, Europe, APAC, South America, and MEA |
Performing market contribution |
North America at 40% |
Key consumer countries |
US, Germany, Japan, France, and Italy |
Competitive landscape |
Leading companies, Competitive Strategies, Consumer engagement scope |
Key companies profiled |
AbbVie Inc., ALK-Abello AS, Bayer AG, Covis Pharma BV, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., and Sanofi SA |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.